Cigna (CI): Evaluating Valuation Following Heartflow Plaque Analysis Coverage Decision
If you have been following Cigna Group (CI) lately, you probably saw news about the company’s decision to cover Heartflow’s recently FDA-cleared Next Generation Plaque Analysis platform across all its business lines, starting October 1. This move does not just look like a policy update; it signals Cigna’s intent to keep pace with other national insurers by supporting the adoption of advanced technologies for coronary care. For shareholders and those thinking about investing, it is worth looking at how this step could affect the company’s broader strategy and valuation.
Over the past year, Cigna’s share performance has left investors with mixed feelings. The stock has climbed about 5% year-to-date, but it remains down roughly…
